부산대학교 도서관

• MGUS and MM have a distinct microenvironment, characterized by a unique distribution of immune cells, including tumor-associated macrophages. • Evaluation of BM tumor microenvironment was performed using IHC quantification of T cells (CD3), macrophages (CD68), and a macrophage subtype (CD163). • The results suggest that there is a significantly lower percentage of CD3+, CD68+, and CD163+ cells in patients with MGUS than in those with untreated MM (p < 0.001). • Interestingly, in a patient treated for myeloma, the percentages of CD3+ and CD68+ cells were the same as those in other patients with untreated myeloma; however, the percentage of CD163+ cells reduced and correlated with low plasma cell count. • If CD163 is correlated with plasma cell burden, then soluble CD163 could be a potential biomarker of disease burden in patients with nonsecretory myelomas, in whom paraproteins and free light chains are ineffective. Plasma cell dyscrasias (PCDs) are a heterogeneous group of diseases, and the most common is monoclonal gammopathy of undetermined significance (MGUS). This premalignant PCD consistently precedes multiple myeloma (MM), with a 1% risk of progression per year. Evading and suppressing the host immune system is an important step in the progression of MGUS to MM. This pilot study was designed to assess whether MGUS and MM have a distinct microenvironment, characterized by a unique distribution of immune cells, including tumor-associated macrophages. Evaluation of bone marrow (BM) tumor microenvironment was performed using immunohistochemical quantification of T cells (CD3), macrophages (CD68), and a macrophage subtype (CD163). The findings were compared between MGUS and MM to determine whether differences existed. The results suggest that there is a significantly lower percentage of CD3-positive, CD68-positive and CD163-positive immune effector cells in BM trephine biopsy samples from patients with MGUS than in those from patients with untreated MM (p < 0.001). Interestingly, in a patient treated for MM, the percentages of CD3+ and CD68+ cells were the same as those in other patients with untreated MM; however, the percentage of CD163+ cells reduced and correlated with low plasma cell count. Future studies are required to investigate whether the percentage of CD163+ cells is correlated with disease burden in patients with MM. If this is the case, then the level of soluble CD163 in plasma could be a potential biomarker of disease burden in patients with nonsecretory myelomas, in whom measurements of levels of paraprotein and free light chains are inconclusive. [ABSTRACT FROM AUTHOR]